A5007198397- Cancer Immunotherapy and Biomarkers
- CAR-T cell therapy research
- Immunotherapy and Immune Responses
- Melanoma and MAPK Pathways
- Renal cell carcinoma treatment
- Colorectal Cancer Treatments and Studies
- Immune Cell Function and Interaction
- Cancer Genomics and Diagnostics
- Monoclonal and Polyclonal Antibodies Research
- Radiation Therapy and Dosimetry
- Cutaneous Melanoma Detection and Management
- Cancer Research and Treatments
- Pancreatic and Hepatic Oncology Research
- Peptidase Inhibition and Analysis
- Nanoplatforms for cancer theranostics
- Brain Metastases and Treatment
- Bladder and Urothelial Cancer Treatments
- Cancer, Stress, Anesthesia, and Immune Response
- Chronic Lymphocytic Leukemia Research
- Acute Myeloid Leukemia Research
- Cell Adhesion Molecules Research
- Lung Cancer Treatments and Mutations
- Immune cells in cancer
- Lung Cancer Research Studies
- HER2/EGFR in Cancer Research
Yale University
2016-2025
Yale Cancer Center
2015-2024
University of New Haven
2011-2024
Sidney Kimmel Comprehensive Cancer Center
2011-2023
Smilow Cancer Hospital
2013-2023
Yale New Haven Hospital
2013-2023
Johns Hopkins University
2014-2023
Apexigen (United States)
2023
Bristol-Myers Squibb (Germany)
2023
University Medical Center
2023
Blockade of programmed death 1 (PD-1), an inhibitory receptor expressed by T cells, can overcome immune resistance. We assessed the antitumor activity and safety BMS-936558, antibody that specifically blocks PD-1.
Nivolumab (a programmed death 1 [PD-1] checkpoint inhibitor) and ipilimumab cytotoxic T-lymphocyte–associated antigen 4 [CTLA-4] have been shown to complementary activity in metastatic melanoma. In this randomized, double-blind, phase 3 study, nivolumab alone or plus was compared with patients
In patients with melanoma, ipilimumab (an antibody against cytotoxic T-lymphocyte-associated antigen 4 [CTLA-4]) prolongs overall survival, and nivolumab the programmed death 1 [PD-1] receptor) produced durable tumor regression in a phase trial. On basis of their distinct immunologic mechanisms action supportive preclinical data, we conducted trial combined advanced melanoma.We administered intravenous doses every 3 weeks for doses, followed by alone (concurrent regimen). The treatment was...
Programmed cell death 1 (PD-1) is an inhibitory receptor expressed by activated T cells that downmodulates effector functions and limits the generation of immune memory. PD-1 blockade can mediate tumor regression in a substantial proportion patients with melanoma, but it not known whether this associated extended survival or maintenance response after treatment discontinued.
PURPOSE To determine the efficacy and toxicity of a high-dose interleukin-2 (IL-2) regimen in patients with metastatic renal cell carcinoma. PATIENTS AND METHODS Two hundred fifty-five assessable were entered onto seven phase II clinical trials. Proleukin (aldesleukin; Chiron Corp, Emeryville, CA) 600,000 or 720,000 IU/kg was administered by 15-minute intravenous (i.v.) infusion every 8 hours for up to 14 consecutive doses over 5 days as clinically tolerated maximum support, including...
Purpose Programmed death 1 is an immune checkpoint that suppresses antitumor immunity. Nivolumab, a fully human immunoglobulin G4 programmed inhibitor antibody, was active and generally well tolerated in patients with advanced solid tumors treated phase I trial expansion cohorts. We report overall survival (OS), response durability, long-term safety non–small-cell lung cancer (NSCLC) receiving nivolumab this trial. Patients Methods (N = 129) heavily pretreated NSCLC received 1, 3, or 10...
Purpose We conducted a retrospective analysis to assess the safety profile of nivolumab monotherapy in patients with advanced melanoma and describe management adverse events (AEs) using established guidelines. Patients Methods Safety data were pooled from four studies, including two phase III trials, who received 3 mg/kg once every 2 weeks. evaluated rate treatment-related AEs, time onset resolution select AEs (those potential immunologic etiology), impact suppressive immune-modulating...
Anti-tumour immune activation by checkpoint inhibitors leads to durable responses in a variety of cancers, but combination approaches are required extend this benefit beyond subset patients. In preclinical models tumour-derived VEGF limits cell activity while anti-VEGF augments intra-tumoral T-cell infiltration, potentially through vascular normalization and endothelial activation. This study investigates how blockade with bevacizumab could potentiate PD-L1 inhibition atezolizumab mRCC....
PURPOSE: A strain of Salmonella typhimurium (VNP20009), attenuated by chromosomal deletion the purI and msbB genes, was found to target tumor inhibit growth in mice. These findings led present phase I study intravenous infusion VNP20009 patients with metastatic cancer. PATIENTS AND METHODS: In cohorts consisting three six patients, 24 melanoma one patient renal cell carcinoma received 30-minute bolus infusions containing 10 6 9 cfu/m 2 VNP20009. Patients were evaluated for dose-related...
The objective was to determine the safety and clinical activity of atezolizumab (MPDL3280A), a humanized programmed death-ligand 1 (PD-L1) antibody, in renal cell carcinoma (RCC). Exploratory biomarkers were analyzed associated with outcomes.Seventy patients metastatic RCC, including clear (ccRCC; n = 63) non-clear (ncc; 7) histologies, received intravenously every 3 weeks. PD-L1 expression scored at four diagnostic levels (0/1/2/3) that based on staining tumor cells tumor-infiltrating...
Purpose Mucosal melanoma is an aggressive malignancy with a poor response to conventional therapies. The efficacy and safety of nivolumab (a programmed death-1 checkpoint inhibitor), alone or combined ipilimumab cytotoxic T-lymphocyte antigen-4 have not been reported in this rare subtype. Patients Methods Data were pooled from 889 patients who received monotherapy clinical studies, including phase III trials; 86 (10%) had mucosal 665 (75%) cutaneous melanoma. also for (n = 35, melanoma; n...
Nivolumab, a monoclonal antibody that inhibits programmed cell death 1, is approved by the US Food and Drug Administration for treating advanced melanoma, renal carcinoma (RCC), non-small lung cancer (NSCLC), other malignancies. Data on long-term survival among patients receiving nivolumab are limited.To analyze overall (OS) identify clinical laboratory measures associated with tumor regression OS.This was secondary analysis of phase 1 CA209-003 trial (with expansion cohorts), which...
Purpose Until recently, limited options existed for patients with advanced melanoma who experienced disease progression while receiving treatment ipilimumab. Here, we report the coprimary overall survival (OS) end point of CheckMate 037, which has previously shown that nivolumab resulted in more achieving an objective response compared chemotherapy regimens ipilimumab-refractory melanoma. Patients and Methods were stratified by programmed death-ligand 1 expression, BRAF status, best prior...
Abstract The immune suppressive molecule programmed death-1 (PD-1) is upregulated in activated T lymphocytes and inhibits T-cell function upon binding to its ligands B7-H1 (PD-L1, CD274) B7-DC (PD-L2, CD273). Substantial experimental data from vitro cell culture systems animal models, more recently clinical trials, indicate that PD-1/PD-1-ligand interactions are a major mechanism of suppression within the tumor microenvironment. Initial studies antibodies directed against PD-1 showed both an...